Home > Boards > US Listed > Biotechs > Adaptimunne Therapeutics (ADAP)

The company and Noile-Immune have announce an agreement

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
jondoeuk Member Profile
 
Followed By 17
Posts 1,271
Boards Moderated 1
Alias Born 10/24/15
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 12/16/2020 5:01:45 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/20/2020 7:37:37 AM
Adaptimmune to Showcase Market Potential for SPEAR T-cell Portfolio and Pipeline with Multiple Cell Therapy Platforms During ... GlobeNewswire Inc. - 11/20/2020 7:30:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/19/2020 9:10:01 AM
Durable Responses with ADP-A2M4 in Synovial Sarcoma with Confirmed Responses in 44% of Patients and Disease Control Rate of 9... GlobeNewswire Inc. - 11/19/2020 9:00:00 AM
Adaptimmune to Host Virtual Investor Day on Friday, November 20th GlobeNewswire Inc. - 11/12/2020 8:00:00 AM
Two Confirmed Responses and Five out of Six Patients with Initial Tumor Reductions from Early Dose Cohorts of SURPASS Trial, ... GlobeNewswire Inc. - 11/9/2020 3:18:19 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/5/2020 4:20:10 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/5/2020 7:41:08 AM
Adaptimmune Reports Q3 Financial Results and Business Update GlobeNewswire Inc. - 11/5/2020 7:30:00 AM
Confidential Treatment Order (ct Order) Edgar (US Regulatory) - 11/4/2020 10:42:34 AM
Adaptimmune to Report Q3 Financial Results and Business Update on Thursday, November 5, 2020 GlobeNewswire Inc. - 10/22/2020 8:00:10 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/15/2020 4:48:05 PM
Adaptimmune Provides Full Contents of its SITC Abstract for the Phase 1 SURPASS Trial GlobeNewswire Inc. - 10/15/2020 4:40:39 PM
Life-Saving Advancements, Treatments Delivered by Companies Invested in Innovation NetworkNewsWire - 10/2/2020 8:45:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/28/2020 10:45:24 AM
Promising Data from Phase 1 Trial with ADP-A2AFP in Liver Cancer at the International Liver Congress Confirm Safety Profile a... GlobeNewswire Inc. - 8/28/2020 10:30:10 AM
Automatic Shelf Registration Statement of Securities of Well-known Seasoned Issuers (s-3asr) Edgar (US Regulatory) - 8/10/2020 5:02:42 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/6/2020 11:17:57 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/6/2020 7:38:25 AM
Adaptimmune Reports Q2 Financial Results and Business Update GlobeNewswire Inc. - 8/6/2020 7:30:10 AM
Adaptimmune Granted Access to PRIority MEdicines (PRIME) Regulatory Support by the European Medicines Agency for ADP-A2M4 for... GlobeNewswire Inc. - 7/23/2020 4:00:10 PM
Adaptimmune to Report Q2 Financial Results and Business Update on Thursday, August 6, 2020 GlobeNewswire Inc. - 7/22/2020 8:00:10 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/1/2020 5:13:49 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/1/2020 5:10:37 PM
jondoeuk   Tuesday, 08/27/19 01:25:35 PM
Re: None
Post # of 133 
The company and Noile-Immune have announce an agreement to develop SPEAR T-cell products expressing IL-7 and CCL19 as a next-generation treatment for cancer patients https://www.globenewswire.com/news-release/2019/08/27/1907041/0/en/Adaptimmune-and-Noile-Immune-Announce-Agreement-to-Develop-SPEAR-T-Cell-Products-expressing-IL-7-and-CCL19-as-a-next-generation-treatment-for-cancer-patients.html

From the PR Karen Miller, ADAP's SVP of Pipeline Research states: ''This agreement with Noile-Immune will enable us to generate next-generation SPEAR T-cells secreting both IL-7 and CCL19*, which may improve proliferation and trafficking of not only our engineered SPEAR T-cells, but also the patient’s own T-cells into solid tumors. This increased T-cell proliferation and trafficking may enhance anti-tumor activity for cancer patients.''

* Here is some preclinical data https://www.nature.com/articles/nbt.4086

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences